Byondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Strengthening Leadership with Multimedia Announcement Byondis B.V., an independent biotechnology company focused on the development of innovative targeted therapies for cancer, has announced a significant leadership transition with the appointment…
Join over 1,000 emergency medicine professionals from across the globe at the Annual Conference 2026, taking place in Birmingham on 28–30 April, as we come together to shape the future of the specialty. With a four-track program covering CPD and research, and up to 17 CPD…
Cosette Pharmaceuticals Broadens Branded Portfolio with Acquisition of SYMPAZAN® and Additional Assets from Assertio Cosette Pharmaceuticals has announced the successful closing of a strategic acquisition that significantly expands its branded product portfolio and reinforces its position in key therapeutic areas.…
Lincotek Announces Appointment of New Global General Manager for Its Medical Division Lincotek has announced the appointment of Gianluca Fioravanti as Global General Manager of its Medical Division, marking a significant leadership move aimed at strengthening the company’s position as…
Humana Inc. Healthy Horizons in Ohio and CPESN USA Introduce Value-Based Pharmacist Quality Rewards Program to Improve Chronic Disease Care Humana Inc., through its Medicaid plan Humana Healthy Horizons in Ohio, has announced an expanded collaboration with CPESN USA aimed…
Cognito Therapeutics Collaborates with Initiative to Replace the “D-Word,” Committing to Remove “Dementia” from All Communications Cognito Therapeutics, a late clinical-stage neurotechnology company focused on developing non-invasive therapies for neurodegenerative diseases, has announced a new partnership with the Initiative to…
Shionogi Highlights Real-World Effectiveness of Fetroja/Fetcroja Against MBL-Producing Enterobacterales at ESCMID Global 2026 Shionogi & Co., Ltd. has unveiled new real-world and surveillance data highlighting the clinical utility of cefiderocol (marketed as Fetroja®/Fetcroja®) in the treatment of highly resistant Gram-negative…
Acadia Pharmaceuticals Expands U.S. Access to DAYBUE STIX for Patients with Rett Syndrome Acadia Pharmaceuticals has announced that DAYBUE® STIX (trofinetide) for oral solution—a newly developed powder formulation of its Rett syndrome therapy—is now broadly available across the United States.…
Endospan Secures U.S. Food and Drug Administration Approval for NEXUS® Aortic Arch Stent Graft System Endospan, a privately held innovator focused on advancing endovascular therapies for complex aortic conditions, has announced a major regulatory milestone with the approval of its…
Alcon Introduces Clareon TruPlus Monofocal and Toric IOLs Featuring Advanced Design Innovations at ASCRS 2026 Alcon a global leader in eye care committed to advancing vision health and improving patient outcomes, has announced the U.S. launch of its latest intraocular…
Affinia Therapeutics Secures Health Canada Clearance to Launch UPBEAT© Phase 1/2 Trial Evaluating AFTX-201 for BAG3-Related Dilated Cardiomyopathy Affinia Therapeutics, a clinical-stage biotechnology company focused on advancing next-generation gene therapies for serious cardiovascular diseases, has announced a key regulatory milestone…
Armatus Reports Promising Breakthrough Data on TVR110, a Vectorized MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A Armatus Bio, a late-preclinical biotechnology company focused on developing next-generation vectorized RNA interference (RNAi) therapies for neuromuscular disorders, has announced the publication of important…